Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing cholangitis (PSC); and is in phase 2 clinical trial to treat systemic sclerosis (SSc). Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel. Show more
Location: Building 7, Tel Aviv, 6158002, Israel | Website: https://www.chemomab.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
13.66M
52 Wk Range
$2.21 - $9.84
Previous Close
$2.36
Open
$2.41
Volume
55,336
Day Range
$2.21 - $2.44
Enterprise Value
3.608M
Cash
10.06M
Avg Qtr Burn
N/A
Insider Ownership
14.06%
Institutional Own.
10.94%
Qtr Updated
09/30/25
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Nebokitug Details Primary Sclerosing Cholangitis | Phase 2 Update |